Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Natera, Inc.    NTRA

NATERA, INC.

(NTRA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

NATERA, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
09/11/2020 | 04:30pm EDT

Item 1.01. Entry into a Material Definitive Agreement.

On September 10, 2020, Natera, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Cowen and Company, LLC and SVB Leerink LLC, as representatives (the "Representatives") of the several underwriters named in Schedule I thereto (the "Underwriters"), in connection with the offer and sale by the Company of 4,166,666 shares of common stock of the Company, par value $0.0001 per share, at a price to the public of $60.00 per share.

Pursuant to the terms of the Underwriting Agreement, the Company granted the Underwriters an option to purchase up to 624,999 additional shares of common stock, which expires on October 10, 2020.

The Company expects to receive net proceeds from this offering of approximately $235.3 million, or approximately $270.6 million if the Underwriters exercise in full their option to purchase additional shares, after deducting underwriting discounts and commissions and other estimated transaction expenses.

The shares are being offered and sold by means of an effective registration statement, including a preliminary prospectus, filed with the U.S. Securities and Exchange Commission on September 9, 2020 (File No. 333-248690) (the "Registration Statement"). The offering is expected to close on September 15, 2020, subject to the satisfaction of specified closing conditions.

A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated by reference herein.

The legal opinion, including the related consent, of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP relating to the legality of the issuance and sale of the shares of the Company's common stock in this offering is filed as Exhibit 5.1 hereto.



Item 8.01. Other Events.



On September 9, 2020, the Company issued a press release announcing the proposed public offering, a copy of which is furnished as Exhibit 99.1 hereto. On September 10, 2020, the Company issued a press release announcing the pricing of the public offering, a copy of which is furnished as Exhibit 99.2 hereto.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.



Exhibit
No.                                       Description

  1.1        Underwriting Agreement dated as of September 10, 2020, among Natera,
           Inc. and J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Cowen and
           Company, LLC and SVB Leerink LLC as representatives of the underwriters
           named therein.

  5.1        Opinion and Consent of Gunderson Dettmer Stough Villeneuve Franklin &
           Hachigian, LLP.

  23.1       Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian,
           LLP (included in Exhibit 5.1).

  99.1       Press release dated September 9, 2020.

  99.2       Press release dated September 10, 2020.

104        Cover Page Interactive Data File (formatted as inline XBRL)

© Edgar Online, source Glimpses


share with twitter share with LinkedIn share with facebook
All news about NATERA, INC.
10/05NATERA : Court Rejects ArcherDX's Motion to Dismiss Natera's Patent Infringement..
PR
09/24NATERA : Medicare Issues Draft Local Coverage Determination for Signatera™..
PR
09/18NATERA : to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting
PR
09/14NATERA : Launches Initiative to Transform the Management of Cancer Patients in O..
PR
09/11NATERA, INC. : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
09/11NATERA : Signatera™ MRD Test Receives a Final Coverage Decision from Norid..
PR
09/11NATERA : Announces Pricing of Follow-On Offering
PU
09/11NATERA : Announces Pricing of Follow-On Offering
PR
09/10NATERA : to Present at the Morgan Stanley 18th Annual Global Healthcare Conferen..
PR
09/09NATERA : Launches Proposed Follow-On Offering
PR
More news
Financials (USD)
Sales 2020 360 M - -
Net income 2020 -203 M - -
Net cash 2020 341 M - -
P/E ratio 2020 -28,1x
Yield 2020 -
Capitalization 5 984 M 5 984 M -
EV / Sales 2020 15,7x
EV / Sales 2021 13,6x
Nbr of Employees 1 039
Free-Float 95,5%
Chart NATERA, INC.
Duration : Period :
Natera, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NATERA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 76,67 $
Last Close Price 71,19 $
Spread / Highest target 26,4%
Spread / Average Target 7,69%
Spread / Lowest Target -15,7%
EPS Revisions
Managers
NameTitle
Stephen Chapman President, Chief Executive Officer & Director
Matthew Rabinowitz Executive Chairman
Robert A. Schueren Chief Operating Officer
Michael Brophy Chief Financial Officer
Jonathan Sheena Director & Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
NATERA, INC.111.31%6 001
BIOMÉRIEUX60.93%17 879
10X GENOMICS, INC.91.02%15 661
DIASORIN S.P.A.66.90%12 455
AUTOBIO DIAGNOSTICS CO., LTD.67.57%10 770
MACCURA BIOTECHNOLOGY CO.LTD83.46%4 321